OR with 95% CI of developing relapsing-onset and progressive-onset MS among subjects categorised by DRB1*15:01 and environmental factors
| Interaction between DRB1*15:01 and smoking | |||||||
| Relapsing-onset MS | Progressive-onset MS | ||||||
| DRB1*15:01 | Smoking | ca/co* | aOR (95% CI)† | aOR (95% CI)‡ | ca/co* | aOR (95% CI)† | aOR (95% CI)‡ |
| – | – | 1109/2543 | 1.0 (reference) | 1.0 (reference) | 71/2543 | 1.0 (reference) | 1.0 (reference) |
| – | + | 1478/2248 | 1.6 (1.4 to 1.8) | 1.7 (1.5 to 1.8) | 132/2248 | 1.8 (1.4 to 2.5) | 2.0 (1.5 to 2.9) |
| + | – | 1626/1002 | 3.8 (3.4 to 4.2) | 3.6 (3.3 to 4.1) | 96/1002 | 3.4 (2.5 to 4.8) | 3.2 (2.3 to 4.4) |
| + | + | 1896/890 | 5.2 (4.6 to 5.8) | 5.3 (4.7 to 5.9) | 157/890 | 5.5 (4.1 to 7.5) | 6.0 (4.4 to 8.2) |
| AP | 0.2 (0.1 to 0.3) | 0.2 (0.1 to 0.3) | 0.2 (0.02 to 0.4) | 0.3 (0.1 to 0.5) | |||
| Interaction between DRB1*15:01 and obesity | |||||||
| DRB1*15:01 | Obesity | ca/co* | aOR (95% CI)† | aOR (95% CI)§ | ca/co* | aOR (95% CI)† | aOR (95% CI)§ |
| – | – | 2422/4595 | 1.0 (reference) | 1.0 (reference) | 187/4595 | 1.0 (reference) | 1.0 (reference) |
| – | + | 66/88 | 1.4 (1.0 to 1.9) | 1.4 (1.0 to 1.9) | 6/88 | 1.7 (0.7 to 4.3) | 1.6 (0.6 to 4.1) |
| + | – | 3293/1818 | 3.5 (3.2 to 3.7) | 3.4 (3.1 to 3.6) | 238/1818 | 3.2 (2.6 to 4.0) | 3.1 (2.5 to 3.8) |
| + | + | 118/25 | 8.7 (5.6 to 13.4) | 8.4 (5.4 to 12.9) | 8/25 | 8.0 (3.4 to 18.8) | 7.4 (2.9 to 17.8) |
| AP | 0.6 (0.4 to 0.8) | 0.5 (0.3 to 0.8) | 0.5 (0.1 to 1.0) | 0.5 (0.01 to 1.0) | |||
| Interaction between DRB1*15:01 and EBNA-1 antibody levels | |||||||
| DRB1*15:01 | EBNA-1 IgG levels | ca/co* | aOR (95% CI)† | aOR (95% CI)¶ | ca/co* | aOR (95% CI)† | aOR (95% CI)¶ |
| – | Low | 510/1836 | 1.0 (reference) | 1.0 (reference) | 67/1836 | 1.0 (reference) | 1.0 (reference) |
| – | High | 1284/1832 | 2.5 (2.2 to 2.9) | 2.5 (2.2 to 2.8) | 110/1832 | 1.7 (1.2 to 2.3) | 1.6 (1.2 to 2.2) |
| + | Low | 446/590 | 2.8 (2.3 to 3.2) | 2.9 (2.4 to 3.4) | 51/590 | 2.(1.7 to 3.6) | 2.4 (1.6 to 3.6) |
| + | High | 2179/886 | 8.9 (7.9 to 10.1) | 9.1 (8.0 to 10.3) | 170/886 | 5.5 (4.1 to 7.5) | 5.5 (4.1 to 7.5) |
| AP | 0.5 (0.4 to 0.6) | 0.5 (0.4 to 0.6) | 0.4 (0.3 to 0.6) | 0.4 (0.3 to 0.6) | |||
| Interaction between DRB1*15:01 and sun exposure | |||||||
| Relapsing-onset MS | Progressive-onset MS | ||||||
| DRB1*15:01 | Sun exposure | ca/co* | aOR (95% CI)† | aOR (95% CI)** | ca/co* | aOR (95% CI)† | aOR (95% CI)** |
| – | High | 1921/3864 | 1.0 (reference) | 1.0 (reference) | 155/3864 | 1.0 (reference) | 1.0 (reference) |
| – | Low | 666/927 | 1.4 (1.3 to 1.6) | 1.4 (1.3 to 1.6) | 48/927 | 1.2 (0.8 to 1.7) | 1.1 (0.8 to 1.6) |
| + | High | 2628/1516 | 3.5 (3.2 to 3.8) | 3.4 (3.1 to 3.7) | 166/1516 | 2.7 (2.2 to 3.5) | 2.7 (2.1 to 3.4) |
| + | Low | 894/376 | 4.8 (4.2 to 5.5) | 4.8 (4.1 to 5.4) | 87/376 | 5.3 (3.9 to 7.1) | 4.8 (3.4 to 6.2) |
| AP | 0.2 (0.1 to 0.4) | 0.2 (0.1 to 0.3) | 0.4 (0.3 to 0.6) | 0.4 (0.2 to 0.6) | |||
*Number of exposed cases and controls.
†Adjusted for study, year of enrolment, age, sex, residential area and ancestry.
‡Adjusted for study, year of enrolment, age, sex, residential area, ancestry, obesity, alcohol consumption, sun exposure habits, snuff use, HLA-A*02:01 and EBNA-1 antibody status.
§Adjusted for study, year of enrolment, age, sex, residential area, ancestry, smoking, alcohol consumption, sun exposure habits, snuff use, HLA-A*02:01 and EBNA-1 antibody status.
¶Adjusted for study, year of enrolment, age, sex, residential area, ancestry, smoking, obesity, alcohol consumption, sun exposure habits, snuff use and HLA-A*02:01.
**Adjusted for study, year of enrolment, age, sex, residential area, ancestry, smoking, obesity, alcohol consumption, snuff use, HLA-A*02:01 and EBNA-1 antibody status.
aOR, adjusted OR; AP, Attributable proportion due to interaction; MS, multiple sclerosis.